Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
According to recent medical studies, one in every seven thousand childbirths is affected by lysosomal storage disease. This number is on the verge of increasing year by year, especially in underdeveloped countries where awareness and medical facilities regarding these diseases are found to be very scarce. This has created a conducive environment for the enzyme replacement therapy market with a staggering valuation of US$ 10,707.6 million expected as of 2024.
ERT is also used in the treatment of various rare diseases such as Gaucher disease and Fabry disease. Advancements in medicare technology and the proliferation of modern and sophisticated facilities in healthcare organizations, both public as well as private, have further led to the expansion of this market. The industry is anticipated to grow at a healthy CAGR of 6.60% from 2024 to 2034.
Government initiatives to make people more aware and lenient reimbursement policies are also responsible for the growth of the market. The market is slated to reach a valuation of US$ 20,289.1 million by the end of 2034.
However, increased costs and unavailability of skilled workforce and healthcare facilities are hindering market growth in some parts of the world. Coupled with a lack of awareness and concerns regarding the efficacy of these treatments, the market has definite obstacles to face in the forecast period.
Attributes | Details |
---|---|
Market Value for 2024 | US$ 10,707.6 million |
Projected Market Value for 2034 | US$ 20,289.1 million |
Value-based CAGR of the Market for 2024 to 2034 | 6.60% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Medicare advancements have led to the advent of novel therapies and treatment options in the healthcare sector. The growth rates of the Gaucher and Pompe diseases enzyme replacement therapy (ERT) market and the hormone replacement therapy market have been mentioned below along with their challenges and ongoing trends.
Inferring to these analytics, it can be confidently projected that the enzyme replacement therapy market is very likely to have a brighter future than the other two.
Enzyme Replacement Therapy Market:
Attributes | Enzyme Replacement Therapy Market |
---|---|
Value-based CAGR (2024 to 2034) | 6.60% |
Projected Market Value (2024) | US$ 10,707.6 million |
Growth Factor | Rapid increase in cases of rare diseases such as Fabry disease, Gaucher disease, Mucopolysaccharidosis, Pompe disease, and lysosomal acid lipase deficiency |
Restraint | Cost remains big challenge in front of economically disadvantaged sections of society |
Trend | Private healthcare facilities collaborating with government bodies so they can make these treatments affordable for cost-sensitive consumers |
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market:
Attributes | Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market |
---|---|
Value-based CAGR (2024 to 2034) | 6.60% |
Growth Factor | Increasing prevalence of lysosomal storage disorders and enzyme deficiencies increasing adoption of Pompe disease treatment. |
Restraints |
|
Trend | Growing advanced technologies and healthcare manufacturers influence market trends |
Hormone Replacement Therapy Market:
Attributes | Hormone Replacement Therapy Market |
---|---|
Value-based CAGR (2024 to 2034) | 3.50% |
Projected Market Value (2024) | US$ 16,825.2 million |
Growth Factor | Rising efforts from players to increase efficiency, cost-efficiency, and safety profile of these therapies propelling market growth |
Restraint | Concerns regarding efficacy of these treatments in minds of general populace |
Trends | Leading manufacturers launching new formulations, including gels, transdermal drugs, and creams |
ERT is used to treat various rare diseases such as Fabry Disease, Gaucher Disease, Mucopolysaccharidosis, etc. Among these, the Mucopolysaccharidosis segment is estimated to hold the largest market share of 24.10% in 2024.
Attributes | Details |
---|---|
Therapeutic Condition | Mucopolysaccharidosis |
Market Share (2024) | 24.10% |
ERTs can be administered through two major routes which are oral and injectable. Among these, the injectable ERT is predicted to hold a market share of 86.90% in 2024.
Attributes | Details |
---|---|
Route of Administration | Injectable |
Market Share (2024) | 86.90% |
Countries | CAGR (2024 to 2034) |
---|---|
Japan | 8.00% |
China | 7.30% |
Canada | 6.90% |
Australia and New Zealand | 6.30% |
Brazil | 6.00% |
The enzyme replacement therapy market in Japan is a promising one. It is slated to grow at a CAGR of 8.00% through 2034.
Japan is currently dealing with a growing aging population. As of 2024, one in every four people living in Japan is above the age of sixty. This has created a conducive environment for ERTs as this demographic is more susceptible to rare diseases.
Responding to these demands, Japanese healthcare companies are also investing billions of dollars in curating novel technologies and therapies to tackle these fatal diseases. For instance, in March 2022, Sanofi's Xenpozyme gained approval in Japan, marking a historic milestone as the inaugural treatment for ASMD.
China is a lucrative country in this market. The enzyme replacement therapy market is inclined to grow at a CAGR of 7.30% through 2034 in the country.
The Chinese government, in the last few years, has been announcing a multitude of schemes and policies to strengthen its medical infrastructure. The recent pandemic has also put a lot of pressure on the Chinese healthcare sector.
All these factors have led to the adoption of best-in-class medical facilities in the country. This improved medical infrastructure has led to the expansion of the ERT market as more people become aware of rare diseases for which this treatment is used.
The future of the Canada ERT market also looks very bright. The market is slated to grow at a CAGR of 6.90% through 2034 in Canada.
The presence of numerous medical institutes and government support in the form of grants and subsidies to the same have proved to be a boon for Canada’s healthcare sector. This has also benefitted ERTs as medicare research institutes have come up with top-tier methodologies for treating deadly diseases in the country.
The Australia and New Zealand ERT market is slated to grow at a CAGR of 6.30% from 2024 to 2034.
Although the incidence of LSDs in Australia and New Zealand is very scarce, both countries are conducting continuous research and development in these fields. The purpose is to entirely terminate these diseases from their population.
Players involved in the ERT market are pouring billions of dollars into making therapies affordable for the common public. For instance, in April 2024, Inozyme Pharma initiated the Phase Ib ENERGY-1 trial, dosing the first infant with INZ-701 enzyme therapy for ENPP1 deficiency, aiming to assess safety and efficacy.
The market in Brazil is very likely to flourish in the coming years. It is slated to grow at a CAGR of 6.00% through 2034.
Lysosomal storage disorders are gradually picking up pace in Brazil. To mitigate these diseases altogether Brazilian companies are collaborating with international partners. They are also investing in research and developing innovative therapies to address lysosomal storage disorders in the country.
The enzyme replacement therapy market is a very limited one as the disease mortality rate is minuscule. This is why very few companies exist in the market, most of which have already established themselves as key players.
The competition is also not that intense as top players hold the majority share of the market. Besides this, these companies are found collaborating with research institutions for more effective and affordable therapies.
Recent Developments in the Enzyme Replacement Therapy Market
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market is expected to be worth US$ 10,707.6 million in 2024.
The enzyme replacement therapy market is expected to reach US$ 20,289.1 million by 2034.
The market is in line to grow at a CAGR of 6.60% from 2024 to 2034.
BioMarin Pharmaceutical Inc., Amicus Therapeutics, Sanofi Genzyme, Alexion Pharmaceuticals, and Ultragenyx Pharmaceutical Inc., are some of the major players in the market.
The market valuation in 2023 was US$ 10,011.1 million.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapeutic Condition 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Condition, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Condition, 2024 to 2034 5.3.1. Fabry Disease 5.3.2. Gaucher Disease 5.3.3. Mucopolysaccharidosis 5.3.3.1. MPS I 5.3.3.2. MPS II 5.3.3.3. MPS IVA 5.3.3.4. MPS VI 5.3.3.5. MPS VII 5.3.4. Pompe Disease 5.3.5. Lysosomal Acid Lipase Deficiency 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Therapeutic Condition, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Therapeutic Condition, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2024 to 2034 6.3.1. Oral Enzyme Replacement Therapy 6.3.2. Injectable Enzyme Replacement Therapy 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Pharmacy Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Pharmacy Type, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Pharmacy Type, 2024 to 2034 7.3.1. Hospital Pharmacies 7.3.2. Specialty Treatment Pharmacies 7.3.3. Retail Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Pharmacy Type, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Pharmacy Type, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Therapeutic Condition 9.2.3. By Route of Administration 9.2.4. By Pharmacy Type 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Therapeutic Condition 9.3.3. By Route of Administration 9.3.4. By Pharmacy Type 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Therapeutic Condition 10.2.3. By Route of Administration 10.2.4. By Pharmacy Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapeutic Condition 10.3.3. By Route of Administration 10.3.4. By Pharmacy Type 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Therapeutic Condition 11.2.3. By Route of Administration 11.2.4. By Pharmacy Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapeutic Condition 11.3.3. By Route of Administration 11.3.4. By Pharmacy Type 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Therapeutic Condition 12.2.3. By Route of Administration 12.2.4. By Pharmacy Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapeutic Condition 12.3.3. By Route of Administration 12.3.4. By Pharmacy Type 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Therapeutic Condition 13.2.3. By Route of Administration 13.2.4. By Pharmacy Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapeutic Condition 13.3.3. By Route of Administration 13.3.4. By Pharmacy Type 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Therapeutic Condition 14.2.3. By Route of Administration 14.2.4. By Pharmacy Type 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapeutic Condition 14.3.3. By Route of Administration 14.3.4. By Pharmacy Type 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Therapeutic Condition 15.2.3. By Route of Administration 15.2.4. By Pharmacy Type 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Therapeutic Condition 15.3.3. By Route of Administration 15.3.4. By Pharmacy Type 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Therapeutic Condition 16.1.2.2. By Route of Administration 16.1.2.3. By Pharmacy Type 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Therapeutic Condition 16.2.2.2. By Route of Administration 16.2.2.3. By Pharmacy Type 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Therapeutic Condition 16.3.2.2. By Route of Administration 16.3.2.3. By Pharmacy Type 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Therapeutic Condition 16.4.2.2. By Route of Administration 16.4.2.3. By Pharmacy Type 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Therapeutic Condition 16.5.2.2. By Route of Administration 16.5.2.3. By Pharmacy Type 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Therapeutic Condition 16.6.2.2. By Route of Administration 16.6.2.3. By Pharmacy Type 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Therapeutic Condition 16.7.2.2. By Route of Administration 16.7.2.3. By Pharmacy Type 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Therapeutic Condition 16.8.2.2. By Route of Administration 16.8.2.3. By Pharmacy Type 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Therapeutic Condition 16.9.2.2. By Route of Administration 16.9.2.3. By Pharmacy Type 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Therapeutic Condition 16.10.2.2. By Route of Administration 16.10.2.3. By Pharmacy Type 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Therapeutic Condition 16.11.2.2. By Route of Administration 16.11.2.3. By Pharmacy Type 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Therapeutic Condition 16.12.2.2. By Route of Administration 16.12.2.3. By Pharmacy Type 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Therapeutic Condition 16.13.2.2. By Route of Administration 16.13.2.3. By Pharmacy Type 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Therapeutic Condition 16.14.2.2. By Route of Administration 16.14.2.3. By Pharmacy Type 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Therapeutic Condition 16.15.2.2. By Route of Administration 16.15.2.3. By Pharmacy Type 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Therapeutic Condition 16.16.2.2. By Route of Administration 16.16.2.3. By Pharmacy Type 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Therapeutic Condition 16.17.2.2. By Route of Administration 16.17.2.3. By Pharmacy Type 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Therapeutic Condition 16.18.2.2. By Route of Administration 16.18.2.3. By Pharmacy Type 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Therapeutic Condition 16.19.2.2. By Route of Administration 16.19.2.3. By Pharmacy Type 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Therapeutic Condition 16.20.2.2. By Route of Administration 16.20.2.3. By Pharmacy Type 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Therapeutic Condition 16.21.2.2. By Route of Administration 16.21.2.3. By Pharmacy Type 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Therapeutic Condition 16.22.2.2. By Route of Administration 16.22.2.3. By Pharmacy Type 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Therapeutic Condition 16.23.2.2. By Route of Administration 16.23.2.3. By Pharmacy Type 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Therapeutic Condition 17.3.3. By Route of Administration 17.3.4. By Pharmacy Type 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Sanofi S.A. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Shire plc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Pfizer Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Alexion Pharmaceuticals Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. BioMarin Pharmaceutical Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Ultragenyx Pharmaceutical Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Johnson & Johnson Services Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Allergan plc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Leadiant Biosciences Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034 Table 2: Global Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 4: Global Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034 Table 5: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 6: North America Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 8: North America Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 10: Latin America Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 12: Latin America Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034 Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 14: Western Europe Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 15: Western Europe Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 16: Western Europe Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034 Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 18: Eastern Europe Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 19: Eastern Europe Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 20: Eastern Europe Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034 Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034 Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 26: East Asia Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 27: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 28: East Asia Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034 Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Therapeutic Condition, 2019 to 2034 Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034 Table 32: Middle East and Africa Market Value (US$ Million) Forecast by Pharmacy Type, 2019 to 2034
Figure 1: Global Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 2: Global Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 3: Global Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 4: Global Market Value (US$ Million) by Region, 2024 to 2034 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034 Figure 8: Global Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 9: Global Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 14: Global Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 15: Global Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 16: Global Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 17: Global Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 18: Global Market Attractiveness by Route of Administration, 2024 to 2034 Figure 19: Global Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 20: Global Market Attractiveness by Region, 2024 to 2034 Figure 21: North America Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 22: North America Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 23: North America Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 24: North America Market Value (US$ Million) by Country, 2024 to 2034 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 28: North America Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 29: North America Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 34: North America Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 35: North America Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 36: North America Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 37: North America Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 38: North America Market Attractiveness by Route of Administration, 2024 to 2034 Figure 39: North America Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 40: North America Market Attractiveness by Country, 2024 to 2034 Figure 41: Latin America Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 43: Latin America Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 44: Latin America Market Value (US$ Million) by Country, 2024 to 2034 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 48: Latin America Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 54: Latin America Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 57: Latin America Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 58: Latin America Market Attractiveness by Route of Administration, 2024 to 2034 Figure 59: Latin America Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 60: Latin America Market Attractiveness by Country, 2024 to 2034 Figure 61: Western Europe Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 62: Western Europe Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 63: Western Europe Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 64: Western Europe Market Value (US$ Million) by Country, 2024 to 2034 Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 68: Western Europe Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 71: Western Europe Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 74: Western Europe Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 75: Western Europe Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 77: Western Europe Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 78: Western Europe Market Attractiveness by Route of Administration, 2024 to 2034 Figure 79: Western Europe Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 80: Western Europe Market Attractiveness by Country, 2024 to 2034 Figure 81: Eastern Europe Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 82: Eastern Europe Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 83: Eastern Europe Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034 Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 94: Eastern Europe Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 97: Eastern Europe Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 98: Eastern Europe Market Attractiveness by Route of Administration, 2024 to 2034 Figure 99: Eastern Europe Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 100: Eastern Europe Market Attractiveness by Country, 2024 to 2034 Figure 101: South Asia and Pacific Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 102: South Asia and Pacific Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 103: South Asia and Pacific Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034 Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 117: South Asia and Pacific Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 118: South Asia and Pacific Market Attractiveness by Route of Administration, 2024 to 2034 Figure 119: South Asia and Pacific Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034 Figure 121: East Asia Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 122: East Asia Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 123: East Asia Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 124: East Asia Market Value (US$ Million) by Country, 2024 to 2034 Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 128: East Asia Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 129: East Asia Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 131: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 132: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 134: East Asia Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 135: East Asia Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 137: East Asia Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 138: East Asia Market Attractiveness by Route of Administration, 2024 to 2034 Figure 139: East Asia Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 140: East Asia Market Attractiveness by Country, 2024 to 2034 Figure 141: Middle East and Africa Market Value (US$ Million) by Therapeutic Condition, 2024 to 2034 Figure 142: Middle East and Africa Market Value (US$ Million) by Route of Administration, 2024 to 2034 Figure 143: Middle East and Africa Market Value (US$ Million) by Pharmacy Type, 2024 to 2034 Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034 Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Therapeutic Condition, 2019 to 2034 Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Therapeutic Condition, 2024 to 2034 Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Therapeutic Condition, 2024 to 2034 Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034 Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034 Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034 Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by Pharmacy Type, 2019 to 2034 Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by Pharmacy Type, 2024 to 2034 Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by Pharmacy Type, 2024 to 2034 Figure 157: Middle East and Africa Market Attractiveness by Therapeutic Condition, 2024 to 2034 Figure 158: Middle East and Africa Market Attractiveness by Route of Administration, 2024 to 2034 Figure 159: Middle East and Africa Market Attractiveness by Pharmacy Type, 2024 to 2034 Figure 160: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Recommendations
Explore Healthcare Insights
View Reports